Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

LumiMeds vs TeleClinic

LumiMeds
Graded #152

Higher grade

vs+7.6000000000000085
TeleClinic
Graded #314

Lower grade

The verdict

LumiMeds takes it — 68.4/100 to 60.8/100.

LumiMeds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telehealth provider with flat-rate compounded GLP-1 pricing on a 3-month plan.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLumiMeds +32
76
44
Dose & formulationEven
64
64
Clinical oversightLumiMeds +2
82
80
Labs & monitoringLumiMeds +1
53
52
FulfillmentTeleClinic +32
65
97
Contract termsLumiMeds +35
55
20
LumiMeds · left barTeleClinic · right bar

The numbers

MetricLumiMedsTeleClinic
WeighScore68.4/10060.8/100
GradeCC
Scorecard rank#152#314
Semaglutide$133/mo (starting dose, compounded)$199/mo (compounded)
Tirzepatide$133/mo (starting dose, compounded)$299/mo (compounded)
CoverageCoverage not published47 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
LumiMeds

Graded #152 · C

Strengths

  • Aggressively low monthly pricing
  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details
TeleClinic

Graded #314 · C

Strengths

  • Names its pharmacy partner — Rush Pharmacy, a licensed 503A compounder — which many compounded-GLP-1 telehealths won't disclose
  • LegitScript certified with flat, published monthly pricing, free shipping, and no insurance required
  • Broad access: 47 states with US-licensed physicians and transparent cash-pay pricing

Where it loses points

  • Compounded semaglutide and tirzepatide only — no brand-name GLP-1 (Wegovy or Zepbound) option
  • Headline $139/$219 rates are first-quarter intro prices billed quarterly; ongoing month-to-month is $199/$299
  • Not available in California, South Carolina, or New Jersey

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard